250 related articles for article (PubMed ID: 35196021)
1. Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia.
Berrien-Elliott MM; Foltz JA; Russler-Germain DA; Neal CC; Tran J; Gang M; Wong P; Fisk B; Cubitt CC; Marin ND; Zhou AY; Jacobs MT; Foster M; Schappe T; McClain E; Kersting-Schadek S; Desai S; Pence P; Becker-Hapak M; Eisele J; Mosior M; Marsala L; Griffith OL; Griffith M; Khan SM; Spencer DH; DiPersio JF; Romee R; Uy GL; Abboud CN; Ghobadi A; Westervelt P; Stockerl-Goldstein K; Schroeder MA; Wan F; Lie WR; Soon-Shiong P; Petti AA; Cashen AF; Fehniger TA
Sci Transl Med; 2022 Feb; 14(633):eabm1375. PubMed ID: 35196021
[TBL] [Abstract][Full Text] [Related]
2. Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation.
Shaffer BC; Le Luduec JB; Forlenza C; Jakubowski AA; Perales MA; Young JW; Hsu KC
Biol Blood Marrow Transplant; 2016 Apr; 22(4):705-709. PubMed ID: 26772158
[TBL] [Abstract][Full Text] [Related]
3. Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant.
Bednarski JJ; Zimmerman C; Berrien-Elliott MM; Foltz JA; Becker-Hapak M; Neal CC; Foster M; Schappe T; McClain E; Pence PP; Desai S; Kersting-Schadek S; Wong P; Russler-Germain DA; Fisk B; Lie WR; Eisele J; Hyde S; Bhatt ST; Griffith OL; Griffith M; Petti AA; Cashen AF; Fehniger TA
Blood; 2022 Mar; 139(11):1670-1683. PubMed ID: 34871371
[TBL] [Abstract][Full Text] [Related]
4. The infusion of ex vivo, interleukin-15 and -21-activated donor NK cells after haploidentical HCT in high-risk AML and MDS patients-a randomized trial.
Lee KH; Yoon SR; Gong JR; Choi EJ; Kim HS; Park CJ; Yun SC; Park SY; Jung SJ; Kim H; Lee SY; Jung H; Byun JE; Kim M; Kim SY; Kim JH; Lee JH; Lee JH; Choi Y; Park HS; Lee YS; Kang YA; Jeon M; Woo J; Kang H; Baek S; Kim SM; Kim HM; Cho KH; Choi I
Leukemia; 2023 Apr; 37(4):807-819. PubMed ID: 36932165
[TBL] [Abstract][Full Text] [Related]
5. Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study.
Choi I; Yoon SR; Park SY; Kim H; Jung SJ; Jang YJ; Kang M; Yeom YI; Lee JL; Kim DY; Lee YS; Kang YA; Jeon M; Seol M; Lee JH; Lee JH; Kim HJ; Yun SC; Lee KH
Biol Blood Marrow Transplant; 2014 May; 20(5):696-704. PubMed ID: 24525278
[TBL] [Abstract][Full Text] [Related]
6. Successful Transfer of Umbilical Cord Blood CD34
Dolstra H; Roeven MWH; Spanholtz J; Hangalapura BN; Tordoir M; Maas F; Leenders M; Bohme F; Kok N; Trilsbeek C; Paardekooper J; van der Waart AB; Westerweel PE; Snijders TJF; Cornelissen J; Bos G; Pruijt HFM; de Graaf AO; van der Reijden BA; Jansen JH; van der Meer A; Huls G; Cany J; Preijers F; Blijlevens NMA; Schaap NM
Clin Cancer Res; 2017 Aug; 23(15):4107-4118. PubMed ID: 28280089
[No Abstract] [Full Text] [Related]
7. Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse.
Shapiro RM; Birch GC; Hu G; Vergara Cadavid J; Nikiforow S; Baginska J; Ali AK; Tarannum M; Sheffer M; Abdulhamid YZ; Rambaldi B; Arihara Y; Reynolds C; Halpern MS; Rodig SJ; Cullen N; Wolff JO; Pfaff KL; Lane AA; Lindsley RC; Cutler CS; Antin JH; Ho VT; Koreth J; Gooptu M; Kim HT; Malmberg KJ; Wu CJ; Chen J; Soiffer RJ; Ritz J; Romee R
J Clin Invest; 2022 Jun; 132(11):. PubMed ID: 35349491
[TBL] [Abstract][Full Text] [Related]
8. Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy.
Berrien-Elliott MM; Becker-Hapak M; Cashen AF; Jacobs M; Wong P; Foster M; McClain E; Desai S; Pence P; Cooley S; Brunstein C; Gao F; Abboud CN; Uy GL; Westervelt P; Jacoby MA; Pusic I; Stockerl-Goldstein KE; Schroeder MA; DiPersio JF; Soon-Shiong P; Miller JS; Fehniger TA
Blood; 2022 Feb; 139(8):1177-1183. PubMed ID: 34797911
[TBL] [Abstract][Full Text] [Related]
9. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
[TBL] [Abstract][Full Text] [Related]
10. Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide.
Rambaldi B; Kim HT; Reynolds C; Chamling Rai S; Arihara Y; Kubo T; Buon L; Gooptu M; Koreth J; Cutler C; Nikiforow S; Ho VT; Alyea EP; Antin JH; Wu CJ; Soiffer RJ; Ritz J; Romee R
Blood Adv; 2021 Jan; 5(2):352-364. PubMed ID: 33496734
[TBL] [Abstract][Full Text] [Related]
11. Clinical grade production of IL-15 stimulated NK cells for early infusion in adult AML patients undergoing haploidentical stem cell transplantation with post-transplant cyclophosphamide.
Rubio-Azpeitia E; Pérez-Corral AM; Dorado-Herrero N; Monsalvo S; Pérez-Balsera G; Fernández-Santos ME; Kwon M; Oarbeascoa G; Bastos-Oreiro M; Falero C; Pascual Izquierdo C; Muñoz-Martínez C; Pérez-Martínez A; Diez-Martin JL; Anguita J
Transfusion; 2022 Feb; 62(2):374-385. PubMed ID: 35023148
[TBL] [Abstract][Full Text] [Related]
12. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia.
Romee R; Rosario M; Berrien-Elliott MM; Wagner JA; Jewell BA; Schappe T; Leong JW; Abdel-Latif S; Schneider SE; Willey S; Neal CC; Yu L; Oh ST; Lee YS; Mulder A; Claas F; Cooper MA; Fehniger TA
Sci Transl Med; 2016 Sep; 8(357):357ra123. PubMed ID: 27655849
[TBL] [Abstract][Full Text] [Related]
13. Impact of Natural Killer Cell-Associated Factors on Acute Leukemia Outcomes after Haploidentical Hematopoietic Stem Cell Transplantation with αβ T Cell Depletion in a Pediatric Cohort.
Glushkova S; Shelikhova L; Voronin K; Pershin D; Vedmedskaya V; Muzalevskii Y; Kazachenok A; Kurnikova E; Radygina S; Ilushina M; Khismatullina R; Maschan A; Maschan M
Transplant Cell Ther; 2024 Apr; 30(4):435.e1-435.e12. PubMed ID: 38278183
[TBL] [Abstract][Full Text] [Related]
14. NK cells and ILCs in tumor immunotherapy.
Sivori S; Pende D; Quatrini L; Pietra G; Della Chiesa M; Vacca P; Tumino N; Moretta F; Mingari MC; Locatelli F; Moretta L
Mol Aspects Med; 2021 Aug; 80():100870. PubMed ID: 32800530
[TBL] [Abstract][Full Text] [Related]
15. A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia.
Fehniger TA; Miller JS; Stuart RK; Cooley S; Salhotra A; Curtsinger J; Westervelt P; DiPersio JF; Hillman TM; Silver N; Szarek M; Gorelik L; Lowdell MW; Rowinsky E
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1581-1589. PubMed ID: 29597002
[TBL] [Abstract][Full Text] [Related]
16. [Clinical Safety of NK Cell in the Prevention of Leukemia Relapse Post-transplantation and in Treatment of the Elderly Leukemia Patients].
Liu J; Zheng XL; Xue M; Zhu L; Ding L; Han DM; Yan HM; Li S; Ma JD; Tan XT; Zhou JX; Guo ZK; Wang HX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Aug; 30(4):1267-1271. PubMed ID: 35981396
[TBL] [Abstract][Full Text] [Related]
17. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients.
Curti A; Ruggeri L; D'Addio A; Bontadini A; Dan E; Motta MR; Trabanelli S; Giudice V; Urbani E; Martinelli G; Paolini S; Fruet F; Isidori A; Parisi S; Bandini G; Baccarani M; Velardi A; Lemoli RM
Blood; 2011 Sep; 118(12):3273-9. PubMed ID: 21791425
[TBL] [Abstract][Full Text] [Related]
18. The early expansion of anergic NKG2A
Roberto A; Di Vito C; Zaghi E; Mazza EMC; Capucetti A; Calvi M; Tentorio P; Zanon V; Sarina B; Mariotti J; Bramanti S; Tenedini E; Tagliafico E; Bicciato S; Santoro A; Roederer M; Marcenaro E; Castagna L; Lugli E; Mavilio D
Haematologica; 2018 Aug; 103(8):1390-1402. PubMed ID: 29700172
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
[TBL] [Abstract][Full Text] [Related]
20. Haploidentical Natural Killer Cell Therapy as an Adjunct to Stem Cell Transplantation for Treatment of Refractory Acute Myeloid Leukemia.
Kulkarni U; Arunachalam AK; Palani HK; Nair RR; Balasundaram N; Venkatraman A; Korula A; Selvarajan S; Lionel S; Balasubramanian P; Maddali M; Abraham A; George B; Mathews V
Cell Transplant; 2023; 32():9636897231198178. PubMed ID: 37706453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]